The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab for recurrent/metastatic adenoid cystic carcinoma: A multicenter, single-arm, phase 2 clinical trial.
 
Olga Zamulko
No Relationships to Disclose
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Jianmin Pan
No Relationships to Disclose
 
Audrey Romano
No Relationships to Disclose
 
Maria Lehn
No Relationships to Disclose
 
Allison Forsythe
No Relationships to Disclose
 
Casey Allen
No Relationships to Disclose
 
Kathryn Wikenheiser-Brokamp
No Relationships to Disclose
 
Christopher Lemmon
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
Dalia El-Gamal
Consulting or Advisory Role - The Ohio State University (I)
Research Funding - Abbvie
Patents, Royalties, Other Intellectual Property - Patent and royalty. (I)
 
Shesh Rai
Stock and Other Ownership Interests - CVS; Humana Healthcare Research; Medpace
 
Trisha Wise-Draper
Stock and Other Ownership Interests - High Enroll
Consulting or Advisory Role - Adaptimmune; Adlai Nortye; Caris Life Sciences; EMD Serono; Genmab; Merck; Need; Replimune
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Caris Life Sciences